In recent times, infertility among both man and woman has become a major concern affecting about 20 per cent of the population worldwide and has been attributed in part to several aetiological factors such as changes in lifestyle, which includes sedentary life, dietary habits, sleep anomalies, environmental pollution, etc. Assisted reproductive technologies (ART) have come to the rescue of many such couples, but presence of metabolic disorders such as obesity, diabetes with insulin resistance (IR) and its secondary complications (micro-and macro-vascular complications), become confounders to the outcome of ART. Cell therapies are arising as a new hope in the management of reproductive disorders and currently, the efficacy of mesenchymal stem cells (MSCs) harvested from the adult sources finds wide application in the management of diseases like stroke, neuropathy, nephropathy, myopathy, wounds in diabetes, etc. Given the capacity of MSCs to preferentially home to damaged tissue and modulate the cellular niche/microenvironment to augment tissue repairs and regeneration, the present review outlines the applications of MSCs in the management of infertility/reproductive disorders.
Introduction
Stem cells (SCs) are known to have a capacity of self renewal and differentiation into various cell types on receiving the desired stimulus. Based on the proliferation rates and differentiation capabilities (potency/plasticity), SCs have been broadly classified into embryonic (ESCs) and adult stem cells (ASCs)/ somatic stem cells 1 . ESCs, the pluripotent SCs derived from inner cell mass of the blastocyst not only replicate indefinitely, but also have a high differentiation capacity to form cell types/tissues from all the three germ layers (ecto-, endo-and mesoderm) and hence carry immense application in tissue regeneration/ replacement following injury/disease. However, several ethical issues, accessibility and availability limit their applications in the clinical world, opening horizons for application of ASCs. ASCs unlike ESCs are multipotent undifferentiated cells derived from juvenile/adult tissues, with limited capacities of selfrenewal and plasticity/differentiation to form different cell types 2 . Based on the source/tissue of derivation, ASCs have also been classified as haematopoietic (HSCs), mammary (MaSCs), intestinal (ISCs), mesenchymal (MSCs), endothelial (EnSCs), neural (NSCs), testicular (TSCs) and olfactory (OSCs) SCs, etc., ASCs have profound therapeutic applications in the management of several complications such as spinal cord injury 3 , liver cirrhosis 4 and peripheral vascular disease 5 with some success. However, limitations on the yield of these SCs, successful homing and/or differentiation to the tissue/organ of interest in vivo from most of the adult sources have limited their clinical application. On the other hand, MSCs among the ASCs have gained importance as an obvious choice for cell therapy because of the potent beneficial effects of immunomodulation, targeted differentiation to tissue of interest, higher proliferation rates, etc.
MSCs are multipotent adult progenitor cells derived from the embryonic mesoderm. In 1970 Friendstein and co-workers isolated this population of cells from the bone marrow as colony-forming unitfibroblasts (CFU-F) with abilities to differentiate into at least adipo-, chondro-and osteocyte lineages 6 . In the past four decades, these multipotent progenitors have been isolated from most of the adult tissues such as adipose tissue, synovium, cartilage, bone, foetal tissues and extra embryonic tissues such as placenta, amniotic fluid and umbilical cord blood and umbilical cord matrix 7 and with extended plasticity to other mesodermal cell types such as myocytes and cardiomyocytes, and transdifferentiation to ectodermal (skin and neurons) and endodermal (insulin-secreting like cells/islet-like cellular aggregates, hepatocytes) lineages 8 . 15, 16 , more recently in the management of infertility (both male and female) 17 .
Metabolic syndrome (MS) and infertility
Metabolic disorders such as insulin resistance (IR) resulting from the increasing incidence of obesity, have serious ramifications on the progression of lifetime health problems such as type II diabetes (T2d), cardiovascular disease (CVd), dyslipidaemia and hypertension. Obesity a component of metabolic syndrome characterized by adipocyte hypertrophy, hypertriglyceridaemia, hyperleptinaemia, hypertriglyceridaemia, etc. is a risk factor for development of diabetes and/or IR, while diabetes another component characterized by hyperglycaemia and/or hyperinsulinaemia is in turn a risk factor for onset and progression of obesity. diabetes and obesity share several similar causes, are inter-related and have reached the state of an epidemic with the incidence expected to reach 330 million worldwide by 2030
18 . Obesity and/or diabetes demonstrate hyperglycaemia, hyperinsulinaemia, hyperleptinaemia, hypercholesterolaemia with or without IR attributing to a wide spectrum of secondary complications with cardiovascular disease, stroke, glomerular nephropathy, diabetic retinopathy, sciatica at one end of the spectrum and infertility (due to an associated disturbance in the hormonal milieu thus affecting the reproductive system) at the other end 19 . development of obesity and IR commonly go handin-hand with the development of fertility problems, but the link between this metabolic state and infertility remains to be defined.
With no preferences, infertility affects both the sexes equally with its own set of complications. The common infertility related complications in obese women include altered ovarian physiology and associated ovulatory disturbances (oligomenorrhoea), increased risk of miscarriages, polycystic ovary syndrome (PCOS), impaired outcomes of assisted reproductive technologies (ART) and pregnancy, and some hormone-dependent forms of cancer, while among obese males it could lead to hypogonadism, decreased sperm concentrations, sperm motility and fertility rates 20 .
In recent years increased body mass index (BMI) has been shown to be associated with reproductive parameters such as poor semen quality, decreased sperm concentration, decreased normal-motile sperm cells and increased dNA fragmentation index 21 among men. However, contradicting studies also showed little or no relation between obesity, sperm concentration and 
Mechanisms underlying infertility in MS
Reproductive function declines at both extremes of human energy balance. A significant proportion of the infertile or sub-fertile populations is obese or overweight, with a plethora of reproductive complications including menstrual dysfunction, anovulation and miscarriage 25 . Both male and female reproductive (hormones) systems are under stringent regulation by the hypothalamus and pituitary glands. Interestingly, reproductive hormones and their analogues, which act through estrogen and testosterone receptors, are targets for obesogenic agents such as endocrine disruptors, thiazolidinediones etc. The common derivation of hormones from cholesterol biosynthesis, which is in turn regulated by signaling molecules such as insulin 26 and leptin, the key molecules in diabetes/ obesity-induced obesity, undoubtedly depicts crosstalk between cholesterol, insulin and leptin signaling pathways with the hormonal signaling pathways 27 . Interestingly, adipokines such as leptin, adiponectin, resistin, etc., and enterokines such as ghrelin have also been implicated in the reproductive functions (normal sexual maturation and reproduction) since these modulate glucose homeostasis, fat homeostasis, influence insulin action and thus may mechanistically link obesity, IR and fertility among both the sexes 28 . A dysregulation of all these adipokines/enterokines is seen with onset and progression of obesity and the condition worsens with the setting in of associated secondary complications such as IR and diabetes mellitus (dM).
The mechanisms leading to/affecting male infertility are mostly ambiguous and undefined 29 and may contribute to a dysregulation of the hypothalamicpituitary-gonadal (HPG) axis. An increase in adipocyte hypertrophy/hyperplasia as a result of obesity can result in both physical changes (increased scrotal temperatures, sleep apnoea and erectile dysfunction) and hormonal changes [altered levels of leptin, oestrogen, insulin (increased) and testosterone (decreased)], which in turn contribute to oligozoospermia, azoospermia, increased dNA fragmentation index (dFI), decreased semen volume, etc. In addition, excess adipose tissue increases peripheral aromatization of androgen to oestrogen due to increased activity of aromatase cytochrome P450 enzyme 20 . Animal studies demonstrate deleterious impact of high oestrogen levels on spermatogenesis 30 . In addition, diminished sex hormone-binding globulin (SHBG) seen in obesity also enhances bioavailable testosterone and estradiol, thus affecting the central negative feedback of excess oestrogen, thereby contributing to decreased hypothalamic pituitary signalling. Oestrogen acts on the hypothalamus to negatively regulate the release of pulses of gonadotropin releasing hormone (GnRH) as well as release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary gland, and estrogen agonists have been shown to have an inhibitory effect on androgen biosynthesis 30 .
Obesity also involves a higher secretion of several adipokines such as leptin, resistin, tumour necrosis factor-α (TnF-α), etc. Excess levels of leptin due to increased secretion from adipose tissue are known to have a deleterious effect on sperm production and the production of androgens by Leydig cells 31 thus directly affect sperm via the endocrine system independent of changes in the HPG axis 32 . Hyperinsulinaemia, which often occurs in obese men, has an inhibitory effect on normal spermatogenesis and can be linked to decreased male fertility by affecting the amount of nuclear and mitochondrial dNA damage in the sperm 33 . In addition, insulin levels also influence the levels of sex hormone binding globulin (sHBG), a glycoprotein that binds to sex hormones. High circulating insulin levels inhibit sHBG synthesis in the liver 34 , leading to a decrease in sHBG thus binding less oestrogen leaving more biologically active, free oestrogen. Increased oxidative stress/ROS as seen in obesity is an independent marker of male infertility leading to dNA damage, deformity and damaged plasma membrane integrity of sperm, acting by impairing the feedback regulation of the HPG axis, in turn affecting spermatogenesis and male reproductive function 35 Obesity also potentially adversely affects the endometrium, implantation and early foetal development 40 , thus increasing the risk of miscarriage 41 . decreased in vitro fertilization (IVF) pregnancy rates in obese women could be partially attributed to the relative gonadotrophin resistance and fewer oocytes retrieved. Similar studies on obese hyperleptinaemic leptin resistant mice demonstrated that fewer embryos reach the blastocyst stage than normal controls 42 possibly implicating for the effects of adipokine/enterokine on ovulatory function. Excess bioavailable androgen may also have detrimental effects on the oocyte, follicle and endometrium.
These mechanisms have been summarized in the Figure. 
Animal models of infertility
Similar to many other disease models such as obesity, diabetes, cancers, pancreatitis, etc. animal models of infertility are also available. While the stubby mice 43 , A-myb knockout mouse 44 and many others 45 demonstrate experimental (genetic) male infertility, AlADIn deficient mice (meiosis and maturation of oocytes affected) 46,47 demonstrate genetic models of female infertility. Overall, more models of male infertility exist compared to those on female infertility. Recently, chemically induced infertility rodent models are also being explored 48, 49 .
WNIN obese mutant rats developed at the animal facility of National Institute of Nutrition, Hyderabad, India, similar to other models of obesity such as Zucker rats, ob/ob mice, etc. demonstrate infertility. Homozygous animals (both sexes) among these mutants did not breed, though reversal of infertility could be achieved partially 50 . Similar to human and other model studies, males among both these mutant models were normal in terms of sperm count, sperm motility and testis histology, however, the decreased libido observed was possibily due to a low circulating testosterone levels, which could also account for observed low testis and accessory gland weights in line with other obese models such as Zucker rats and human subjects. Female mutant rats on the other hand, exhibit delayed puberty, irregular oestrus cycles with small ovaries and short and stumpy uterine horns. Absence of 
Management of infertility
Though both the sexes are at risk/ are contributors for infertility, 30-40 per cent of the reproductive failure is contributed by the male counterpart. Grossly, causes of infertility among females could be grouped into ovulatory problems (ammhenorrhoea, abnormalities of thyroid gland, increased stress levels) (35%), pelvic and tubal factors (50%) (endometriosis, scarred tissue/ adhesions and distorted fallopian tubes) and other such as cervical (stenosis, sperm allergy) and uterine (uterine polyps or fibroids) factors (10%), while on the other hand, male infertility could be because of a number of genetic and environmental factors in addition to low sperm counts, abnormal sperm morphology (shape), and low sperm motility and varicocele 55 . Management of infertility in animal models has been successful to some extent. Most commonly employed strategies include food restriction (50-70%), adrenelectomy, in both sexes, administration of hormones such as testosterone or estrogen, etc., However these results have not been to satisfaction since neither techniques restore infertility completely 50 . ART such as in vitro fertilization (IVF), intrauterine insemination (IUI) etc. and administration of hormones such as oestrogen, testosterone, glucocorticoids etc. are among the choices for management of infertility in both males and females. However, being invasive, expensive and hence non-affordable and with several side-effects, all of these strategies have their own disadvantages, though some success has been demonstrated. Studies in experimental models have shown promises and stem cell therapy for management of infertility is gaining importance.
Management of female infertility:
Ovulation is a complex event in which hormonal signals and physical events are linked in a delicate balance. Women ovulate most effectively in their late teens and early twenties. By age 35-38, most women may experience a decline in the ability to ovulate effectively. Ovulation can be seriously affected by (i) abnormalities of the thyroid gland, (ii) overproduction of prolactin (a hormone leading to breast milk production), (iii) excessive male hormone (androgens) and (iv) physical stress, psychological stress and extreme lifestyle changes.
Premature ovarian failure is another cause of female infertility. Studies by Azmy et al 56 , have shown the reversal of experimentally induced (using cyclophosphamide) premature ovarian failure in rat model. Their studies revealed that intravenous injection of bone marrow (BM)-MSCs derived from male rats reversed hypoestrogenic and hypergonadotrophic state of experimental rats in the treated group as evidenced by serum levels of FSH and E2, resurrection of ovarian folliculogenesis and corpus luteum formation confirmed from the cytological and histopathological studies. dectection of sry gene expressing y chromosome in the ovarian tissues in the treated group corroborates the concept that injected/infused MSCs augment tissue regeneration by homing/incorporating into the tissue structure and/or by paracrine effects. Johnson et al 54 , showed that bone marrow grafts to female mice, and possibly humans, could produce new follicles and oocytes in the recipient ovary.
Another important cause of female infertility is endometroisis. Endometrium is a dynamic tissue that undergoes cycles of growth and regression with each menstrual cycle. This preparation of the endometrium is associated with a period of hyperproliferation and angiogenesis 58 , which points towards the dynamics of resident stem cell population. Endometrial polyps arise from endometrial overgrowth and may cause intermenstrual bleeding, irregular bleeding, and menorrhagia 
Management of male infertility:
Male infertility is commonly due to deficiencies in the semen, and semen quality is used as a surrogate measure of male fecundity. Male germ cells are derived from a founder population of primordial germ cells (PGCs) that are set aside early in embryogenesis. After birth, PGCs differentiate to spermatogonial stem cells in the male which are responsible for maintaining spermatogenesis throughout life by continuous production of daughter cells that differentiate into spermatozoa 64, 65 . Causes of male infertility are more attributed to sperm dysfunctions in terms of their number, morphology and motility. Erectile dysfunction is another emerging cause for male infertility. MSCs have again come to rescue in the management of male infertility. drusenheimer and co-workers 66 , showed that hBMMSCs could transdifferentiate into putative male germ cells that could sustain sperm production. Their studies revealed that these transdifferentiated male germ cells expressed early germ cell markers Oct4, Fragilis, Stella and vasa and male germ cell specific markers Dazl, TSPy, Piwil2 and Stra8. This was also substantiated by other studies 67, 68 which demonstrated that adult ESCs/ BM-MSCs from mouse/human could differentiate into Leydig cells or adrenocortical cells (i.e., steroidogenic cells), thus paving way for treatment of infertility related complications. In addition, MSCs derived from adipose tissue 69 and umbilical cord blood 70 have also shown similar potential. Further studies in this direction have also come from the Japanese group working at kyoto University towards differentiation of embryonic stem cell from mouse to form functional spermatogonial cells in vitro and in vivo, with a capacity to fertilize mouse oocyte when implanted into female mice 71 .
Limitations for therapeutic use
There are several problems that limit the therapeutic use of MSCs at present 72, 73 . Poor engraftment and limited differentiation under in vivo conditions are major obstacles for efficient therapeutic use of mSCs 73 . Since the frequency of spontaneous differentiation of MSCs in the host tissue is extremely rare, therapeutic use of MSCs depends on the ability to control their in vivo differentiation into functional cells with high efficiency and purity
73 . An additional limitation is the potential of MSCs to differentiate into unwanted mesenchymal lineages 74 , which could impair their therapeutic use.
Conclusion
Because of their immunomodulatory ability, self-renewal and differentiation capacity, MSCs are promising therapeutic agents for improvement of cardiac function and treatment of cardiomyopathy, nephropathy, and wounds in diabetic patients. Among stem cells, MSCs have several advantages for therapeutic use such as ability to migrate to the sites of tissue injury, strong immunosuppressive effects, better safety after infusion of allogenic MSCs, and lack of ethical issues, such as those related to the application of human embryonic stem cells. However, there are several outstanding problems including potential risk of malignant transformation of MSCs, unwanted mesenchymal lineages differentiation, and suboptimal targeted differentiation, which need to be addressed before mSCs are defined as a novel and efficient therapeutic agent in the management of infertility.
